BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19

• 

  Events

  Oxford Nanopore Biopharma Day, Philadelphia

  Invitation: Oxford Nanopore Biopharma Day, Philadelphia -- Register to join us on October 9th.

  September 19, 2025
• 

  BioCT
• 

  BioNJ
• 

  NewYorkBio
• 

  Life Sciences PA
• 

  RI Bio
• 

  Invivyd
• 

  Immunology and inflammation

  Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered

  Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to analysts at William Blair.

  September 19, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee

  The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric priority review voucher program, which allows for expedited drug reviews.

  September 19, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Immuno-oncology

  Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer

  Investors had been “holding out hope” that there remained a regulatory path forward for RP1, but results of Replimune’s Type A meeting with the FDA do not appear to support this, according to BMO Capital Markets.

  September 19, 2025

   · 

  2 min read

   · 

  Tristan Manalac